How health technology reassessment can support disinvestment in China's national drug reimbursement list

BMJ. 2023 Jun 15:381:e068917. doi: 10.1136/bmj-2021-068917.

Abstract

A requirement to assess actual use of reimbursed medicines would enable transparent, documented, evidence based decisions on disinvestment, say Lizheng Shi and colleagues

MeSH terms

  • Biomedical Technology*
  • China
  • Humans